Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

被引：0

作者：

Castelli, Barbara ^{[1
]}

Tellini, Marco ^{[1
]}

Guidi, Melina ^{[1
]}

Di Nicola, Marco ^{[1
]}

Giunti, Laura ^{[1
]}

Buccoliero, Anna Maria ^{[2
]}

Censullo, Maria Luigia ^{[1
]}

Iacono, Alessandro ^{[3
]}

Desideri, Isacco ^{[4
]}

Genitori, Lorenzo ^{[5
]}

Sardi, Iacopo ^{[1
]}

Fonte, Carla ^{[1
]}

机构：

[1] Meyer Childrens Hosp IRCCS, Neurooncol Dept, Florence, Italy

[2] Meyer Childrens Hosp IRCCS, Pathol Dept, Florence, Italy

[3] Meyer Childrens Hosp IRCCS, Radiol Dept, Florence, Italy

[4] Careggi Hosp, Radiotherapy Dept, Florence, Italy

[5] Meyer Childrens Hosp IRCCS, Neurosurg Dept, Florence, Italy

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

high-grade glioma; MEK inhibitors; target therapy; dabrafenib; trametinib; pleomorphic xanthoastrocytoma; BRAFV600E; BRAF inhibitors; PLEOMORPHIC XANTHOASTROCYTOMA; BRAF; INHIBITION; ADULTS;

D O I：

10.3389/fonc.2024.1359093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 BRAFV600E mutated. Due to very poor prognosis, there are a few described cases of high-grade glioma (HGG) patients treated with the combined target therapy as third-line treatment. The emergence of optimized sequencing strategies and targeted agents, including multimodal and systemic therapy with dabrafenib plus trametinib, will continue to broaden personalized therapy in HGG improving patient outcomes.

引用

页数：6

共 35 条

[31] Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, Vivek
Baik, Christina
Kirkwood, John M.
[J]. TRENDS IN CANCER, 2020, 6 (09): : 797 - 810
[32] BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience
Trinder, Sarah M.
McKay, Campbell
Power, Phoebe
Topp, Monique
Chan, Bosco
Valvi, Santosh
McCowage, Geoffrey
Govender, Dinisha
Kirby, Maria
Ziegler, David S.
Manoharan, Neevika
Hassall, Tim
Kellie, Stewart
Heath, John
Alvaro, Frank
Wood, Paul
Laughton, Stephen
Tsui, Karen
Dodgshun, Andrew
Eisenstat, David D.
Endersby, Raelene
Luen, Stephen J.
Koh, Eng-Siew
Sim, Hao-Wen
Kong, Benjamin
Gottardo, Nicholas G.
Whittle, James R.
Khuong-Quang, Dong-Anh
Hansford, Jordan R.
[J]. FRONTIERS IN ONCOLOGY, 2023, 13
[33] Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Wen, Patrick Y.
Stein, Alexander
van den Bent, Martin
De Greve, Jacques
Wick, Antje
de Vos, Filip Y. F. L.
von Bubnoff, Nikolas
van Linde, Myra E.
Lai, Albert
Prager, Gerald W.
Campone, Mario
Fasolo, Angelica
Lopez-Martin, Jose A.
Kim, Tae Min
Mason, Warren P.
Hofheinz, Ralf-Dieter
Blay, Jean-Yves
Cho, Daniel C.
Gazzah, Anas
Pouessel, Damien
Yachnin, Jeffrey
Boran, Aislyn
Burgess, Paul
Ilankumaran, Palanichamy
Gasal, Eduard
Subbiah, Vivek
[J]. LANCET ONCOLOGY, 2022, 23 (01) : 53 - 64
[34] The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, Jimin
Dong, Xiaoduo
Yap, Jiajun
Hu, Jiancheng
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[35] Editorial: Molecular Advances in Diagnosis and Treatment of CNS Tumors
Zhang, Zhao-Hui
Lin, Ming-Tseh
Chen, Liam
[J]. FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 →